Trial Profile
Circulating immune-profile as a predictive biomarker of response to Nivolumab in patients with advanced pre-treated non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress